Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aggressive reduction in cholesterol levels can reduce risk for stroke by 16 percent

11.08.2006
Promising research offers important information for physicians and patients

According to data from the National Stroke Association, up to 40 percent of patients who have had a stroke will experience a second stroke within five years of the first. An international team of researchers recently completed a study to determine if the cholesterol-lowering drug Lipitor® (atorvastatin calcium) would reduce the occurrence of a second stroke. The Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) team of investigators, led by Dr. K. Michael Welch, neurologist and President and CEO of Rosalind Franklin University of Medicine and Science, published their research in today's issue of the New England Journal of Medicine.

The SPARCL study included 4,731 patients with no history of heart disease who had experienced a stroke or TIA (mini stroke) within six months of study enrollment. The patients had mildly elevated cholesterol levels, and received either 80 mg of Lipitor® or a placebo; they were then monitored for an average of five years.

Study findings indicate that patients taking Lipitor® experienced a 16-percent reduction in the risk of secondary stroke compared with patients taking a placebo. Lipitor patients also saw a 35-percent reduction in the risk of major coronary events (cardiac death, non-fatal heart attacks, or resuscitated cardiac arrest) compared to the patients taking placebo. "These cardiovascular results are remarkable in a population not known to have had heart disease," said principal investigator, Dr. K. Michael Welch.

The SPARCL study researchers conclude that their results support the initiation of statin (i.e., Lipitor®) treatment shortly after a stroke or TIA. "We believe that the findings indicate that Lipitor 80 should become an established part of secondary stroke prevention," said Dr. Welch.

An analysis of the SPARCL data was designed and conducted after the study ended to explore the types of strokes -- ischemic or hemorrhagic -- that occurred among patients in the study. Eighty-five percent of the strokes in this trial were ischemic. Patients taking Lipitor® experienced a 22-percent reduction in the risk of ischemic stroke.

Also, the number of patients in the analysis who experienced hemorrhagic stroke was very small. There were more patients in the Lipitor® group who experienced this type of stroke (2.3 percent), compared to patients taking placebo (1.4 percent). However, the overall benefit in terms of reducing the risk of stroke was still significant despite this increase, and there was no difference in the number of deaths from hemorrhagic stroke between the two treatment groups.

Every year, an estimated 15 million people worldwide suffer strokes, and 10 million will either remain disabled or die. Strokes also exact a heavy economic toll, with the lifetime cost of treating one patient with a stroke averaging more than $3 million. Reducing the risk of stroke through the application of new data, such as those revealed by the SPARCL investigation, is a key priority in cardiovascular medicine.

The 16-percent reduction in secondary stroke risk that was achieved through aggressively reducing cholesterol levels of study patients is indeed significant. "These data are important information for physicians because patients who have had a stroke are at much greater risk for suffering another one, yet treatment options to reduce their risk are limited," commented Dr. Welch.

SPARCL is an investigator-led trial coordinated by an independent steering committee and funded by Pfizer, Inc. For more information, contact Dr. K. Michael Welch, principal investigator, at michael.welch@rosalindfranklin.edu.

Kathleen Peterson | EurekAlert!
Further information:
http://www.rosalindfranklin.edu
http://www.lifeindiscovery.com

More articles from Health and Medicine:

nachricht Cardiac diseases: when less is more
30.03.2017 | Universitätsspital Bern

nachricht TSRI researchers develop new method to 'fingerprint' HIV
29.03.2017 | Scripps Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

NASA laser communications to provide Orion faster connections

30.03.2017 | Physics and Astronomy

Reusable carbon nanotubes could be the water filter of the future, says RIT study

30.03.2017 | Studies and Analyses

Unique genome architectures after fertilisation in single-cell embryos

30.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>